Patienten mit Typ-2-Diabetes: Fenofibrat in Kombination mit Statinen

Melden Sie sich bitte hier kostenlos und unverbindlich an, um den Inhalt vollständig einzusehen und weitere Services von www.medmedia.at zu nutzen.

Zur Anmeldung

AutorIn: Dr. Dorothea Schied-Reuscher

5. Medizinische Abteilung mit Endokrinologie, Rheumatologie und Akutgeriatrie, Wilhelminenspital der Stadt Wien


AutorIn: Prim. Univ.-Prof. Dr. Peter Fasching

5. Medizinische Abteilung mit Endokrinologie, Rheumatologie und Akutgeriatrie, Wilhelminenspital der Stadt Wien


Literatur:

– European Association for Cardiovascular Prevention & Rehabilitation, Reiner Z et al., ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS), Eur Heart J 2011; 32:1769–818

– Catapano AL et al., ESC/EAS Guidelines for the management of dyslipidaemias, The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS), Atherosclerosis 2011; 217:3–46

– Davis TM et al., Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: The Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study. Diabetologica 2011; 54:280–90

– Action to Control Cardiovascular Risk in Diabetes (ACCORD) Study Group, Gerstein HC et al., Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358(24):2545–59

– ACCORD Study Group, Ginsberg HN et al., Effects of combination lipid therapy in type 2 diabetes mellitus. New Engl J Med 2010; 362(17):1563–74

– ACCORD Study Group, ACCORD Eye Study Group, Chew EY et al., Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med 2010; 363:233–44

– Keech A et al., FIELD study investigators, Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005; 366:1849–61

– Jun M et al., Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. Lancet 2010; 375:1875–84

– Sacks FM et al., Combination lipid therapy in type 2 diabetes. N Engl J Med 2010; 363:692–4

– Keating GM, Croom KF, Fenofibrate: a review of its use in primary dyslipidaemia, the metabolic syndrome and type 2 diabetes. Drugs 2007; 67(1):121–53

– Backman JT et al., Plasma concentrations of active simvastatin acid are increased by gemfibrozil. Clin Pharm Ther 2000; 68:122–9

– Jones PH, Davidson MH, Reporting rate of rhabdomyo­lysis with fenofibrate + statin versus gemfibrozil + any statin, Am J Cardiol 2005; 95:120–2

– Ansquer JC et al., Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo controlled study in type 2 diabetes: results from the Diabetes Atherosclerosis Intervention study (DAIS). Am J Kidney Dis 2005; 45:485–93

– Scott R et al., Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Diabetes Care 2009; 32:493–8

– Moutzouri E et al., Management of dyslipidemias with fibrates, alone and in combination with statins: role of delayed-release fenofibric acid. Vasc Health Risk Manag 2010; 6:525–39

– Tenenbaum A, Fisman EZ, Fibrates are an essential part of modern anti-dyslipidemic arsenal: spotlight on atherogenic dyslipidemia and residual risk reduction. Cardiovasc Diabetol 2012; 11:125

– Tenenbaum A, Fisman EZ, Balanced pan-PPAR activator bezafibrate in combination with statin: comprehensive lipids control and diabetes prevention? Cardiovasc Diabetol 2012 Nov 14; 11:140. doi: 10.1186/1475-2840-11-140

– Pauciullo P et al., Efficacy and safety of a combination of fluavastatin and bezafibrate in patients with mixed hyperlipidaemia (FACT study). Atherosclerosis 2000; 150:429–36

– Eliav O et al., High-dose fluvastatin and bezafibrate combination treatment for heterozygous familial hypercholesterolemia. Am J Cardiol 1995; 76(2):76A–79A

– Leitersdorf E et al., Efficacy and safety of a combination fluvastatin-bezafibrate treatment for familial hypercholesterolemia: comparative analysis with a fluvastatin-cholestyramine combination. Am J Cardiol 1994; 96:401–7

– Klempfner R, Goldenberg I, Fisman EZ, Matetzky S, Amit U, Shemesh J, Tenenbaum A, Comparison of statin alone versus bezafibrate and statin combination in patients with diabetes mellitus and acute coronary syndrome. Am J Cardiol 2014 Jan 1; 113(1):12–6. doi: 10.1016/j.amjcard.2013.08.033. Epub 2013 Oct 2


UIM 06|2014

Herausgeber: o. Univ.-Prof. Dr. Günter J. Krejs, Österreichische Gesellschaft für Innere Medizin
Publikationsdatum: 2014-08-04